Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.

September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...

September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...

FRIDAY, Sept. 6, 2024 -- The risk for lung cancer is high in patients with rheumatoid arthritis (RA) and pulmonary complications, according to a study...

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers

Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers

A new report has revealed for the first time the wide-ranging and increasing health dangers posed by long-term weather extremes in the UK, as the...

BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...

BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...